相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
Wing H. Tong et al.
BLOOD (2014)
Shedding light on the asparaginase galaxy
Carmelo Rizzari
BLOOD (2014)
Safety Profile of Asparaginase Erwinia chrysanthemi in a Large Compassionate-Use Trial
Paul V. Plourde et al.
PEDIATRIC BLOOD & CANCER (2014)
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group
Wanda L. Salzer et al.
BLOOD (2013)
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
Lise Willems et al.
BLOOD (2013)
Optimizing asparaginase therapy for acute lymphoblastic leukemia
Carmelo Rizzari et al.
CURRENT OPINION IN ONCOLOGY (2013)
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
Lynda M. Vrooman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Ching-Hon Pui et al.
BLOOD (2012)
Erwinia asparaginase in pediatric acute lymphoblastic leukemia
Wanda Salzer et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia
C. Liu et al.
LEUKEMIA (2012)
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Daniele Covini et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2012)
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials
Andrea Willer et al.
BLOOD (2011)
L-Asparaginase Treatment in Acute Lymphoblastic Leukemia
Rob Pieters et al.
CANCER (2011)
Polyethylene Glycol-conjugated L-asparaginase Versus Native L-asparaginase in Combination With Standard Agents for Children With Acute Lymphoblastic Leukemia in Second Bone Marrow Relapse: A Children's Oncology Group Study (POG 8866)
Joanne Kurtzberg et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations
Beata Zalewska-Szewczyk et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2009)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
Wendy Stock et al.
BLOOD (2008)
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
I. M. Appel et al.
LEUKEMIA (2008)
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
Meir Wetzler et al.
BLOOD (2007)
Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials
Ramya Ramanujachar et al.
PEDIATRIC BLOOD & CANCER (2007)
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Albert Moghrabi et al.
BLOOD (2007)
L-asparaginase from Erwinia chrysanthemi 3937:: Cloning, expression and characterization
Georgia A. Kotzia et al.
JOURNAL OF BIOTECHNOLOGY (2007)
The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia
Beata Zalewska-Szewczyk et al.
LEUKEMIA & LYMPHOMA (2007)
FDA drug approval summary: Pegaspargase (Oncaspar (R)) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)
Patricia Anne Dinndorf et al.
ONCOLOGIST (2007)
Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden -: A comparison between a pediatric protocol and an adult protocol
Helene Hallbook et al.
CANCER (2006)
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse:: A children's oncology group study (CCG-1941)
Mohammad Jarrar et al.
PEDIATRIC BLOOD & CANCER (2006)
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
A Pession et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - The past, the present and recommendations for the future
VI Avramis et al.
CLINICAL PHARMACOKINETICS (2005)
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia - Children's Cancer Group Study CCG-1961
EH Panosyan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia
DS Hawkins et al.
CLINICAL CANCER RESEARCH (2004)
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands
JM de Bont et al.
LEUKEMIA (2004)
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients
B Wang et al.
LEUKEMIA (2003)
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults?: Comparison of the French FRALLE-93 and LALA-94 trials
N Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase
BK Albertsen et al.
MEDICAL AND PEDIATRIC ONCOLOGY (2002)
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies:: results of a randomized European Organisation for Research and Treatment of Cancer -: Children's Leukemia Group phase 3 trial
M Duval et al.
BLOOD (2002)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac:: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system
BK Albertsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries
BK Albertsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration
BK Albertsen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
LB Silverman et al.
BLOOD (2001)
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment:: Results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study -: A report from the Associazione Italiana Ematologia Oncologia Pediatrica
C Rizzari et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Engineering the substrate specificity of Escherichia coli asparaginase II.: Selective reduction of glutaminase activity by amino acid replacements at position 248
C Derst et al.
PROTEIN SCIENCE (2000)
Pegylated asparaginase (Oncaspar™) in children with ALL:: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols
HJ Müller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E-coli L-asparaginase as first exposure
C Rizzari et al.
ANNALS OF ONCOLOGY (2000)
分享论文
